We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+11.94%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.73B
AUM Growth
+$6.46M
Cap. Flow
-$42.8M
Cap. Flow %
-2.48%
Top 10 Hldgs %
30.81%
Holding
279
New
77
Increased
40
Reduced
47
Closed
83

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$14.4M
2
ILMN icon
Illumina
ILMN
+$11.2M
3
ICUI icon
ICU Medical
ICUI
+$10.4M
4
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
+$9.5M
5
OM icon
Outset Medical
OM
+$8.23M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.5M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
LUNG icon
Pulmonx
LUNG
+$10.1M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$9.8M
5
EVH icon
Evolent Health
EVH
+$7.06M

Sector Composition

Rank Sector Weight
1 Healthcare 34.81%
2 Industrials 0.32%
3 Materials 0.15%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
201
PUT
Alnylam Pharmaceuticals
ALNY
$30B
– –
-50,000
Closed -$7.29M
APYX icon
202
CALL
Apyx Medical
APYX
$126M
– –
-300,000
Closed -$1.76M
ARKK icon
203
CALL
ARK Innovation ETF
ARKK
$6.44B
– –
-200,000
Closed -$7.98M
ARQT icon
204
Arcutis Biotherapeutics
ARQT
$3.3B
– –
-100,000
Closed -$2.13M
ATRA icon
205
CALL
Atara Biotherapeutics
ATRA
$83.1M
– –
-8,000
Closed -$1.56M
AVTR icon
206
Avantor
AVTR
$9.42B
– –
-155,000
Closed -$4.82M
BHC icon
207
PUT
Bausch Health
BHC
$2.32B
– –
-300,000
Closed -$2.51M
BMY icon
208
PUT
Bristol-Myers Squibb
BMY
$130B
– –
-200,000
Closed -$15.4M
BNTX icon
209
CALL
BioNTech
BNTX
$23.3B
– –
-80,000
Closed -$11.9M
CDXS icon
210
Codexis
CDXS
$172M
– –
-337,154
Closed -$3.53M
CGC
211
PUT
Canopy Growth
CGC
$431M
– –
-350,000
Closed -$9.97M
CLDX icon
212
PUT
Celldex Therapeutics
CLDX
$3.52B
– –
-100,000
Closed -$2.7M
COGT icon
213
Cogent Biosciences
COGT
$6.76B
– –
-238,787
Closed -$2.15M
DXCM icon
214
PUT
DexCom
DXCM
$34.3B
– –
-94,000
Closed -$7.01M
EVH icon
215
Evolent Health
EVH
$471M
– –
-230,000
Closed -$7.06M
EW icon
216
Edwards Lifesciences
EW
$53.6B
– –
-20,700
Closed -$1.97M
EXAS
217
PUT
DELISTED
Exact Sciences
EXAS
– –
-100,000
Closed -$3.94M
HCA icon
218
PUT
HCA Healthcare
HCA
$89.8B
– –
-50,000
Closed -$8.4M
HQY icon
219
CALL
HealthEquity
HQY
$8.82B
– –
-250,000
Closed -$15.3M
HSIC icon
220
PUT
Henry Schein
HSIC
$10.1B
– –
-70,000
Closed -$5.37M
HUM icon
221
Humana
HUM
$46.7B
– –
-6,400
Closed -$3M
IART icon
222
PUT
Integra LifeSciences
IART
$1.35B
– –
-123,900
Closed -$6.69M
ILMN icon
223
PUT
Illumina
ILMN
$29.1B
– –
-61,680
Closed -$11.1M
IMCR icon
224
Immunocore
IMCR
$1.77B
– –
-6,419
Closed -$239K
IMUX icon
225
PUT
Immunic
IMUX
$217M
– –
-33,550
Closed -$1.16M
7 8
9
10 11

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2022 Portfolio in Review

As of Q3 2022, Pura Vida Investments held 279 positions worth $1.73B, up 0.38% from $1.72B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Pura Vida Investments's Q3 2022 filing shows 77 new, 40 increased, 47 reduced and 83 closed positions. Its largest new stake was Illumina: 56,540 shares worth $10.5M. The largest sale was Biogen, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Industrials and Materials.

  • Pura Vida Investments's largest Q3 2022 buy was Illumina: 56,540 shares worth $10.5M.
  • Pura Vida Investments added most to United Therapeutics in Q3 2022, an estimated $14.4M increase.
  • Pura Vida Investments's biggest Q3 2022 reduction was Biogen, cutting an estimated $20.5M.
  • Pura Vida Investments fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $13.9M.
  • Pura Vida Investments's ten largest holdings make up 31% of its $1.73B portfolio in Q3 2022.
  • Pura Vida Investments opened 77 new positions and closed 83 in Q3 2022.
  • Pura Vida Investments's portfolio value rose 0.38% quarter-over-quarter to $1.73B.

Based on Pura Vida Investments's 13F filing for Q3 2022, filed 14 Nov 2022.